JOHN CARTER WILLIAMS
Pilots at B St, San Diego, CA

7624422, Nov 24, 2009

Feb 13, 2004

10/778837

John Leslie Williams - San Diego CA, US
Brian Costello - Los Angeles CA, US
John Patrick Ravenel - Escondido CA, US
John Pelly - La Jolla CA, US
Ryan Tadashi Nakawatase - San Diego CA, US
Thomas Paul Walpole - Carlsbad CA, US

Preventsys, Inc. - Carlsbad CA

H04L 12/24, H04L 29/06, H04L 12/26

726 1, 726 3, 726 25

A prevention-based network auditing system includes an audit repository storing network information gathered by a plurality of heterogeneous information sources. A semantic normalization module identifies semantic equivalencies in the gathered information, and generates a map listing for each fact gathered by an information source, an equivalent fact or set of facts gathered by each of the other information sources. A network policy is then uniformly applied to the information that is identified as being semantically equivalent.

7737154, Jun 15, 2010

Dec 20, 2004

10/596648

Zhiyong Luo - New York NY, US
Deborah H Slee - Cardiff CA, US
John Williams - San Diego CA, US

Smithkline Beecham (Cork) Limited - Currabinny, Carrigaline, County Cork

C07D 487/04, A61K 31/519, A61P 25/24, A61P 25/22

5142591, 544281

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

6984643, Jan 10, 2006

Jul 1, 2003

10/611049

Daisy Joe Du Bois - Palo Alto CA, US
Long Mao - San Diego CA, US
Daniel Harry Rogers - San Diego CA, US
John Patrick Williams - San Diego CA, US

Roche Palo Alto LLC - Palo Alto CA

C07D 401/12, A61K 31/506, A31P 11/06

514256, 514274, 514275, 544316, 544332, 544335

Compounds of Formula (I): wherein Aris aryl; Aris hydrogen, cycloalkyl, aryl or heteroaryl; Z is —C(═O) or a single bond; R, R, R, Rand Rare independently hydrogen or alkyl optionally substituted with hydroxy; alk is an alkylene chain of one to six carbon atoms; X is —O—, —NR(where Ris hydrogen or alkyl), (CRR)(where Rand Rare independently in each occurrence hydrogen or alkyl and m is an integer from 0 to 3), or —S(O)(wherein n is an integer from 0 to 2); or prodrugs thereof, and pharmaceutically acceptable salts thereof, are inhibitors of CCR3 useful for treating eosinophil induced diseases such as asthma.

2003015, Aug 14, 2003

Nov 14, 2002

10/294490

Mustapha Haddach - San Diego CA, US
John Williams - San Diego CA, US
Michael Schwaebe - San Diego CA, US

Neurocrine Biosciences, Inc. - San Diego CA

A61K031/538, A61K031/519, C07D498/14, C07D487/14

514/229800, 514/267000, 544/089000, 544/250000, 544/251000

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animal, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein m, R, R, R, A, X, Y and Z are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

2007029, Dec 20, 2007

Dec 20, 2004

10/596646

Zhiyong Luo - New York NY, US
Deborah Slee - Cardiff CA, US
John Tellew - La Jolla CA, US
John Williams - San Diego CA, US
Xiaohu Zahang - San Diego CA, US

A61K 31/519, A61P 1/00, A61P 25/22, A61P 25/24, A61P 9/10, C07D 487/04

514259300, 544281000

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R, R, R, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.